Contribute Try STAT+ Today

In a little-noticed move, the Biden administration has hit the pause button on a rule that would prevent the federal government from using a controversial legal provision for combating the high prices of products developed with taxpayer dollars.

The move amounts to an about-face after the White House left the rule, which was proposed earlier this year by the Trump administration, on its regulatory agenda last month. However, the latest decision suggests the Biden administration is responding to pressure to widen access to medicines and vaccines, especially those funded in part by the U.S. treasury, in the face of the Covid-19 pandemic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment